Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Arq Bras Oftalmol ; 69(5): 701-5, 2006.
Artigo em Português | MEDLINE | ID: mdl-17187139

RESUMO

PURPOSE: To evaluate the costs and efficacy of type A botulinum toxin in the treatment of essential blepharospasm and hemifacial spasm. METHODS: Pacients with essential blepharospasm and hemifacial spasm had their files analyzed. All patients were treated with type A botulinum toxin (Dysport) between April 2002 and May 2004 at the Oculoplastic Clinics of "Santa Casa de São Paulo". Twenty-seven patients presented essential blepharospasm and 23 presented hemifacial spasm. Information about the patient's degree of satisfaction after treatment, complaints and personal costs were recorded by a questionnaire, and information about the costs of Dysport treatment were obtained at the administration department of "Santa Casa de São Paulo". Wilcoxon and Mann-Whitney tests were used for statistical analysis. RESULTS: 1- The annual treatment costs were R Dollars 1,239.32 for essential blepharospasm and R Dollars 661.72 for hemifacial spasm. 2- The patient's annual costs were R Dollars 145.48 for essential blepharospasm and R Dollars 6.07 for hemifacial spasm. 3- The hospital's annual costs for the treatment were R Dollars 1,095.84 for essential blepharospasm and R Dollars 535.65 for hemifacial spasm. 4- Dysport treatment is successful in both essential blepharospasm and hemifacial spasm. CONCLUSIONS: The costs of essential blepharospasm and hemifacial spasm treatment with Dysport are high, mainly because of the toxin price. On economic analysis of health, we can conclude that this procedure has an excellent cost-benefit ratio.


Assuntos
Blefarospasmo/tratamento farmacológico , Blefarospasmo/economia , Toxinas Botulínicas Tipo A/economia , Espasmo Hemifacial/tratamento farmacológico , Espasmo Hemifacial/economia , Neurotoxinas/economia , Idoso , Idoso de 80 Anos ou mais , Blefarospasmo/fisiopatologia , Toxinas Botulínicas Tipo A/uso terapêutico , Análise Custo-Benefício , Feminino , Seguimentos , Espasmo Hemifacial/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Neurotoxinas/uso terapêutico , Satisfação do Paciente , Estatísticas não Paramétricas , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...